Author: Customer Service

Total Gross Proceeds of $299,000,000 Million, Including Underwriter Over-Allotment New York, NY, Feb. 05, 2026 (GLOBE NEWSWIRE) — Colombier Acquisition Corp. III (the “Company”) (NYSE: CLBR U) announced today that it closed its initial public offering of 29,900,000 units, including 3,900,000 units offered pursuant to the exercise of the underwriters’ over-allotment option. The offering was priced at $10.00 per unit, generating total gross proceeds of $299,000,000. Each unit consists of one Class A ordinary share and one-eighth of one redeemable warrant, with each whole warrant exercisable to purchase one Class A ordinary share at a price of $11.50 per share. The units are currently listed on the New York Stock Exchange (“NYSE”) and trading under the ticker symbol “CLBR U.” After the securities comprising the units begin separate...

CHICAGO, Feb. 05, 2026 (GLOBE NEWSWIRE) — Century Aluminum Company (NASDAQ: CENX) will report fourth quarter 2025 earnings on Thursday, February 19, 2026, after market close. The news release will be issued through GlobeNewswire. The company will hold a follow-up conference call on Thursday, February 19, 2026, at 5:00 p.m. Eastern time. The earnings call will be webcast live on the Century Aluminum Company website, located at www.centuryaluminum.com. Plan to begin the registration process at least 10 minutes before the live call is scheduled to begin. A replay of the webcast will be archived and available for replay approximately two hours following the live call. Contact: Investors: Chad Rigg, 312.696.3132, investorrelations@centuryaluminum.comMedia: Tawn Earnest, 614.698.6351, tawn.earnest@centuryaluminum.com 

End of a strong year for Festi: Strong operational performance in the quarter and the results for the year significantly exceeded the company’s initial guidance. Main results in Q4 2025Sales of goods and services amounted to ISK 44,956 million, an increase of 7.2% between years. Margin from sales of goods and services amounted to ISK 11,415 million, an increase of 11.2% from the previous year. Profit margin was 25.4%, decreases by 0.2 p.p. from Q3 2025 but increases by 0.9 from Q4 2024. EBITDA amounted to ISK 4,255 million, increasing by 43.9% between years but 14.8% without the effects of one-off cost in Q4 2024. Profit for the quarter amounted to ISK 1,870 million, increasing by 35.3% between years without the effects of one-off cost in Q4 2024. Net Cash from operating activities amounted to ISK 1,508 million and increases by...

(Oslo, Norway, 5 February 2025) Hexagon Purus ASA (“Hexagon Purus” or the “Company”), a world leading manufacturer of zero-emission mobility and infrastructure solutions, has through one of its wholly owned subsidiaries entered into an agreement to divest its aerospace business to Space Exploration Technologies Corp. (“SpaceX”). The transaction comprises the sale of 100% of the shares of Hexagon Masterworks Inc. (“Masterworks”), which supplies high-pressure composite storage cylinders for aerospace and space launch applications in North America, and for hydrogen mobility applications. The hydrogen business is not part of the transaction perimeter, and Masterworks’ existing hydrogen customer contracts are intended to be transferred to other parts of Hexagon Purus prior to closing. The transaction implies an enterprise value...

OMA SAVINGS BANK PLC, STOCK EXCHANGE RELEASE ON 5 FEBRUARY 2026 AT 18.00 P.M. EET, INSIDER INFORMATION Oma Savings Bank Plc: The Financial Supervisory Authority has initiated a hearing procedure concerning imposing possible administrative sanctions on Oma Savings Bank Plc Oma Savings Bank Plc (OmaSb or the Company) announced on 3 May 2024 that the Financial Supervisory Authority had filed a request for a police investigation concerning suspected securities market offences related to the Company and was concurrently investigating the need to impose administrative sanctions on the Company. OmaSb announced on 11 December 2025 that the police investigation and consideration of charges in the securities market offences had been concluded and that no requests for criminal sanctions had been presented to be imposed on OmaSb in the matter. The...

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR PUBLIC DISSEMINATION IN THE UNITED STATES. CALGARY, Alberta, Feb. 05, 2026 (GLOBE NEWSWIRE) — Petrus Resources Ltd. (“Petrus” or the “Company“) (TSX: PRQ) is pleased to announce that, due to investor demand, it has entered into an amended agreement with Haywood Securities Inc. on behalf of a syndicate of underwriters (collectively, the “Underwriters“), to increase the size of its previously announced “bought deal” private placement offering to approximately $14.5 million (the “Upsized Offering“). The Underwriters have agreed to purchase, on a bought-deal basis, a total of 8,285,714 common shares of the Company (“Shares“) a price of $1.75 per Share (the “Issue Price“) for gross proceeds of approximately...

Podcasts Combine for Over 30 Million Downloads Across Network, For Your Amusement Marks 25th New Podcast for 2026 Fiscal Year LOS ANGELES, Feb. 05, 2026 (GLOBE NEWSWIRE) — PodcastOne (Nasdaq: PODC), a leading publisher and podcast sales network, announced today that it entered into a multiyear extension with The Prosecutors, as well as renewal agreements with Bitch Bible and Some More News. Additionally, PodcastOne has acquired the sales and distribution rights to For Your Amusement in a multiyear deal. Hosted by Jackie Schimmel, Bitch Bible – which joined PodcastOne in 2024 – is a podcast that dares to say what many are thinking, but only a bitch would say. Expect unfiltered and unapologetic discussions about sex, millennial struggles, pop culture, social faux-pas and hopefully, an insightful takeaway. Nothing is off...

Bagsværd, Denmark and Plainsboro, NJ, 5 February 2026 – Novo Nordisk today issued the following statement regarding the announcement by Hims & Hers that they will unlawfully mass-market an unapproved, inauthentic, and untested knockoff semaglutide pill. “The action by Hims & Hers is illegal mass compounding that poses a significant risk to patient safety. Novo Nordisk will take legal and regulatory action to protect patients, our intellectual property and the integrity of the US gold-standard drug approval framework. This is another example of Hims & Hers’ historic behaviour of duping the American public with knock-off GLP-1 products, and the FDA has previously warned them about their deceptive advertising of GLP-1 knock-offs. The American Diabetes Association®’s Obesity Association™ recently published new standards...